Abstract. The prognostic abilities of breast cancer gene expression signatures are due mostly to the detection of proliferation activity. One of the strongest, yet simple and well-reproducible proliferation-associated prognostic factors is the mitotic activity index (MAI). However: a) counting mitotic figures is regarded by many histopathologists as cumbersome and time-consuming, and b) most available immunohistochemical markers are much weaker predictors than the MAI. We have investigated the spatio-temporal sub-cellular distribution of the Serine 2481-autophosphorylated form of mTOR (PP-mTOR Ser2481 ) during the G 1 /S-to-M-phase transition both in cultured cancer cells and in cancer tissue specimens. Using a high-resolution, automated confocal high-content imaging system, we observed that mitotic cells notably accumulated a distinct pattern of nuclear and cytoplasmic immunolabelings of PP-mTOR Ser2481 . Parallel experiments examining site-specific phosphorylation (i.e., Serine 10 and Serine 28) of the G 2 /M marker Histone H3 (PP-H3) revealed that PP-H3 Ser10/Ser28 staining efficiently detected mitotic cells from prophase until the beginning of anaphase, but not during late anaphase, telophase and cytokinesis. PP-mTOR Ser2481 staining associated near and between separating chromosomes not only during early mitotic stages but also to the midzone and to midbody at ana/telophase through cytokinesis. We then evaluated the usefulness of PP-mTOR Ser2481 immunostaining for improving the efficiency of mitotic counting using. Anti-PPmTOR Ser2481 -labeled mitotic figures (MFs) were easily seen and permitted a quick identification of mitotic hotspots in formalinfixed cancer tissues, even at low magnification. Importantly, average mitotic counts were significantly higher when using PP-mTOR Ser2481 staining than with the hematoxylin and eosin (H&E) protocol in breast cancer core biopsies. Mitotic count based on PP-mTOR Ser2481 immunostaining increased tumor grade by one grade in 2 of 9 breast carcinomas. These findings warrant forthcoming studies to confirm both the accuracy and the prognostic value of PP-mTOR Ser2481 as a novel high-contrast immunohistochemical mitosis marker in larger populations of human breast carcinomas.
Introduction
Recent molecular profiling studies of breast cancer disease have demonstrated the pivotal importance of the genetic makeup of breast tumors. These high-throughput gene expression analyses have shown close associations between molecular portrait of breast carcinomas and tumor biologic and clinical behavior (1) (2) (3) (4) (5) . Thus, biological processes associated with breast cancer clinical outcome appear to strongly depend on the molecular breast cancer subtypes as originally reported (i.e., basal-like, HER2
+ , normal-breast like and luminal epithelial/estrogen receptor ER + ) (6) (7) (8) (9) . In line with this renewed molecular taxonomy of breast cancer, several prognostic/predictive gene expression signatures with little overlap in their constituent genes have been identified in the last few years (e.g., ONC-16, NKI-70, EMC-76, NCH-70, CON-52, p53-32, CSR, GGI-128, and CCYC) (10) (11) (12) (13) (14) (15) . Interestingly, two recent meta-analyses have exposed that the prognostic abilities of breast cancer subtyping and prognosis signatures may largely depend on the detection of proliferation activity (16, 17) . The largest meta-analysis of as a novel high-contrast mitosis marker in breast cancer core biopsies publicly available breast cancer gene expression and clinical data revealed that, when the role of constituent genes of nine prognostic signatures was dissected using gene coexpression modules of key biological breast cancer processes (i.e., proliferation, ER and HER2 signaling), all the prognostic signatures exhibited a similar prognostic performance in the entire dataset comprising 2,833 breast tumors. Interestingly, poor outcomes appeared to mostly act through elevated expression of proliferation genes (16) . Similarly, a comprehensive meta-analysis integrating both clinicopathologic and gene expression data identified proliferation as the most important component of several prognostic signatures (14) . Therefore, when connecting traditional prognostic factors, gene expression-based breast cancer subtyping, and prognostic signatures, proliferation is the strongest parameter predicting clinical outcome in some breast cancer subtypes (i.e., ER + /HER2) and the common denominator of most prognostic/predictive gene signatures (15) .
One of the strongest yet simple and well-reproducible proliferation-associated prognostic factors is the mitotic activity index (MAI) (17) (18) (19) . However: a) counting mitotic figures is regarded as cumbersome and time-consuming, requiring the experience of trained histopathologists (20, 21) , and b) most available immunohistochemical markers are much weaker predictors than the MAI (22) . In this regard, immunohistochemical detection of Histone H3 Ser10 phosphoprotein has been recently shown to be a simple and reliable method for quantifying proliferative potential as a mitosis marker in breast cancer patients (23) (24) (25) . Histone H3 becomes phosphorylated on Serine 10 when the chromosomes condense during prophase and remains phosphorylated until telophase, at which stage it becomes dephosphorylated by specific phosphatases (26) (27) (28) . Some non-mitotic (interphasic) cells display also labelling with anti-phospho-Histone H3 Ser10 , a phenomenon that has been related to chromatin relaxation and gene expression (23, 29) . However, these nuclei can be easily distinguished because of their specific (weak and punctuated) staining pattern and, therefore, they not interfere with the accurate determination of the mitotic index using phospho-Histone H3 Ser10 staining (23) (24) (25) .
Because some kinase-active forms of the mammalian target of rapamycin (mTOR) appears to act as mitotic survival checkpoints (30, 31) we herein explored the spatio-temporal sub-cellular distribution of the Serine 2481-autophosphorylated form of mTOR (PP-mTOR Ser2481 ) during the G 1 /S-to-M-phase transition. To definitely established whether PP-mTOR Ser24812 specifically marks the M-phase of cell cycle, we took advantage of a high-resolution, automated confocal imaging system, we concurrently monitored the spatio-temporal subcellular distribution of the G 2 /M-associated site-specific phosphorylation (i.e., Ser10 and Ser28) of Histone H3 (26, 32, 33) and that of the Serine 2481-autophosphorylated form of mTOR in cultured cancer cells. Second, we have tested the utility of PP-mTOR Ser2481 immunolabelling as an aid to the rapid, reliable, and objective quantification of cellular proliferation in human cancer tissues.
Materials and methods
Cell lines and culture conditions. HeLa human cervical cancer cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and routinely grown in improved MEM (IMEM) supplemented with 10% fetal bovine serum (FBS), 1% penicillin (100 U/ml)/streptomycin (100 μg/ml), and 2 mM L-glutamine. Cells were maintained at 37˚C in a humidified atmosphere of 95% air and 5% CO 2 . Cells were screened periodically for Mycoplasma contamination.
Reagents. The following antibodies were used in this study, mouse mAb anti-phospho-Histone H3 (Ser10) [ Tumors. Paraffin-embedded blocks of 22 malignant tumors were retrieved from the routine files of the Department of Pathology, Dr Josep Trueta University Hospital of Girona (Catalonia, Spain). Tumor types are shown in Table I . Of 12 breast carcinomas, 3 were mastectomies and 9 represented core biopsies. The remaining tumor samples were excisional biopsies.
Immunohistochemistry. Immunohistochemical analyses were performed on formalin-fixed, paraffin-embedded block tissues from the cancer tissue collection in our Department of Pathology, Dr Josep Trueta University Hospital of Girona including core biopsies and surgical specimens. Tumor tissues were analyzed for PP-mTOR Ser2481 state using standardized immunohistochemical techniques and robotic autostainers (Dako Cytomation, Inc.). Briefly, a 3-μm section of the cancer tissue was placed on positively charged glass microscope slides. Deparaffinization involved incubation of the slides in xylene followed by graded alcohol series in a routine manner. The PP-mTOR Ser2481 expression state was evaluated using heatinduced epitope retrieval (HIER) followed by incubation with 1:50 dilution of the phospho-mTOR (Ser2481) antibody (no. 2974; Cell Signaling Technology, Inc.). Binding results were visualized with the Envision + system (Dako Cytomation), which uses a horseradish peroxidase-labelled polymer that is conjugated with secondary antibodies. Diaminobenzidine was used as the chromogen.
Counting of mitotic figures (MFs).
The definition of observable mitotic figures (MFs) in the H&E staining protocol was adopted according to van Diest et al (20) and comprised the following criteria: a) absence of nuclear membrane signifying the end of prophase, b) presence of condensed chromosomes, either clotted (beginning metaphase), arranged in a plane (metaphase or anaphase) or in separate clots (telophase), the latter counted as one MF. Hypercromatic nuclei, fragmented chromatin and apoptotic nuclei were ignored.
All H&E sections were carefully examined (magnification, x400) and the one showing the highest proliferation, usually in the peripheral growing areas of the excisional biopsies, was selected for assessment of mitotic activity. Starting from the subjectively most mitotically active area of the tumor and moving between consecutive fields, approximately 10 consecutive high power fields (HPF) were counted with an Olympus BH-2 microscope. In core biopsies samples without apparent area of highest mitotic activity, counting of MFs started at the edge of the cylinder. Once starting in an area, additional fields were selected randomly. No attempts were made to maximize the counting by selecting those fields with a higher number. Mitotic counts were performed without knowledge of the results of the PP-mTOR Ser2481 -based immunohistochemical staining. PP-mTOR Ser2481 -positive MFs were counted in the same way as in H&E-stained sections and indicated as number of labeled MFs per 10 HPF. Mitotic Ser 2481 -phosphorylation of mTOR begins just prior to prophase. Because nuclei at this stage would not be identified as MFs on conventional H&E staining, PP-mTOR Ser2481 -positive nuclei in the presence of nuclear membrane were excluded from quantification. Because the MF would be higher in tumors with abundant cytoplasm, PP-mTOR Ser2481 -positive cytoplasm was only accepted as MF if condensed chromosomes were clearly recognizable in the same cell.
Statistical analysis. Statistical analysis was carried out with XLSTAT (Addinsoft™). Wilcoxon's paired test was carried out to compare the mitotic figure count assessed with H&E staining and PP-mTOR Ser2481 immunolabelling in 10 consecutive fields (magnification, x400) of the 22 surgical specimens (excisional biopsies) and core biopsies. Spearman's correlation was used to assess the relationship between variables. For all analyses, a P<0.05 was considered to be significant. (32, 33) . There is tight correlation between Histone H3 phosphorylation and mitotic chromosome condensation initiating during early prophase (32) (33) (34) (35) and metaphase chromosomes are always found to be heavily phosphorylated for Histone H3 (33,34,36 ). Accordingly, immunolabeling Table I . Tumor types analyzed.
Results

Confocal microscopy analyses reveal that
EB, excisional biopsies; CB, core biopsies. with the G 2 /M markers phospho-Ser 10 Histone H3 (Fig. 1 ) and phospho-Ser 28 Histone H3 (Fig. 2) became up-regulated in mitotic cells from the end of G 2 -phase until the beginning of anaphase, with a weak positivity remaining at late anaphase that became undetectable at telophase and during cytokinesis.
In prophase cells, identified by the appearance of chromosome condensation, PP-mTOR Ser2481 staining could be seen throughout the nucleus (Figs. 1 and 2 ). Although this faint punctuate staining seemed to be distributed along the arms of the chromosomes, there was no evident co-localization between PP-mTOR Ser2481 and Ser 10 -and Ser 28 phosphorylated forms of Histone H3. PP-mTOR Ser2481 reactivity was somewhat prominent at centromere-like structures and both the number of these structures and their staining intensity with PP-mTOR Ser2481 correlated with the degree of chromatin condensation. However, we failed to observe a co-localization between PP-mTOR Ser2481 with the centromere proteins INCENP and aurora-B (data not shown). In general, there was a trend towards a decrease in general chromosomal staining as the cell progressed towards metaphase. When phospho-Ser 10 Histone H3 and phospho-Ser 28 Histone H3 were confined to the metaphase plate, PP-mTOR Ser2481 was most prominent as a broad cytoplasmic staining. In some cases, PP-mTOR Ser2481 appeared to accumulate in some extent as discrete centrosomallike foci at the spindle poles ( Figs. 1 and 2 ). Chromosomeassociated reactivity of PP-mTOR Ser2481 was not longer detected from the onset of anaphase when chromatids are pulled apart and start migrating towards the poles. Rather, PP-mTOR Ser2481 reactivity was then detected in association with the mitotic spindle, particularly in the region of the stembodies at the spindle equator. This localization of PP-mTOR Ser2481 persisted during the furrowing process. Thus, at the completion of telophase, prominent staining of PP-mTOR Ser2481 was apparent as doublet on either side of the midbody within the intracellular bridge. The detection of PP-mTOR Ser2481 to the center of the midbody at the cleavage furrow area reached its maximum during early telophase and, with time, the intensity decreased at the junction between the two daughter cells. Concurrent with this progressive loss of PP-mTOR Ser2481 at the intercellular bridge was an increase in reactivity within the reforming nuclei ( Figs. 1 and 2 ).
Immunohistochemical staining with an anti-PP-mTOR
Ser2481
antibody allows rapid and precise determination of mitotic activity in breast cancer core biopsies. Second, we tested if PP-mTOR Ser2481 -based immunohistochemical staining could objectively detect and quantitate the mitotic fraction in human cancer tissues. All mitotic figures assessed by H&E-based standard histology were strongly labelled with the anti-PPmTOR Ser2481 antibody in breast cancer core biopsies. Indeed, PP-mTOR Ser2481 staining permitted quick identification of the area of highest mitotic activity for subsequent counting in human cancer tissues, even at low magnification (Fig. 3) . Mitotic figures from prophase through metaphase, anaphase, and telophase, could be easily identified with PP-mTOR Ser2481 immunohistochemical staining (Fig. 4) . Furthermore, we confirmed that cells displaying morphological features of apoptosis or necrosis were negative for PP-mTOR Ser2481 , thus suggesting that mitotic count based on PP-mTOR Ser2481 immunohistochemistry could be more accurate than the determined on H&E staining. Hence, eye-catching PP-mTOR Ser2481 -positive spots were particularly useful when trying to detect mitotic cells in high-grade breast carcinomas with dense cellularity and numerous apoptotic or necrotic cells (data not shown).
Third, we finally compared mitotic counts in PPmTOR Ser2481 -stained and H&E-stained paraffin-embedded sections according to the Scarff-Bloom-Richardson histoprognostic grading (37) modified by Elston and Ellis (38) , in a pilot study including 9 breast cancer core biopsies (Fig. 5) . A strong correlation was found between the two methods. Importantly, 8 of the 9 invasive ductal breast carcinomas showed a higher number of PP-mTOR Ser2481 -positive mitotic cells compared with H&E staining. Thus, average mitotic counts were significantly higher when using PP-mTOR Ser2481 labeling (mean 16, range 1-71) than with the H&E staining protocol (mean=5; range 0-28) in breast cancer core biopsies (p=0.011; Wilcoxon's non-parametric paired test). Moreover, when the global histoprognostic score was re-evaluated on the basis of phospho-Ser 2481 mTOR staining in this small sample of breast carcinomas, it was shifted from grade 2 to grade 3 in two cases. Whereas the phospho-mTOR (Ser2481) antibody (no. 2974, Cell Signaling Technology, Inc.) worked very well on core needle biopsies, the staining results were largely unsatisfactory in a majority of excisional biopsies including lumpectomy specimens (Fig. 6a) . Indeed, average mitotic counts were significantly lower when using PP-mTOR Ser2481 labeling (mean 12, range 0-50) than with the H&E staining protocol (mean 21, range 3-38) in large specimens (p=0.036, Wilcoxon's non-parametric paired test) (Fig. 6b) .
Discussion
In breast carcinomas, the mitotic count is of paramount importance in determining the prognosis and is an integral part of the widely used Elston-Ellis modification of Scarff-BloomRichardson grading system (37), also known as the Nottingham combined histological grade or Nottingham grading system (38) . Because all the mitotic phases are well discernible by using the H&E staining protocol, some authors have suggested that immunohistochemical detection of mitoses is not necessary in breast cancer as mitotic counts are highly reproducible if adhering to a strict protocol (20) . However, mitotic figures are rarely encountered, due to the short duration of the M-phase in comparison to the other phases of the cell cycle, and their detection requires high magnification thus making the screening of large tissue areas tedious and time-consuming. Moreover, when the demonstration of the M-phase is crucial, none of the most available immunohistochemical proliferation markers [e.g., cyclin D1, proliferating cell nuclear antigen (PCNA), Ki67] assesses the actual rate of cell division. Indeed, when using methods aimed to reveal DNA synthesis we should consider that this process might occur also prior to apoptosis or might indicate DNA repair. Some kinase-active forms of the mammalian target of rapamycin (mTOR), a master integrator of cell growth and division in response to cell energy state, nutrient status, and growth factor stimulation (39) (40) (41) , unexpectedly appear to act as mitotic survival checkpoints. Yaba et al have revealed that PP-mTOR Ser2448 is present at very high levels during the M-phase in ovarian granulosa cells (30) . They further reported that PP-mTOR Ser2448 , but not total mTOR, was enriched on or near the mitotic spindle and also near the contractile ring during cytokinesis. Phosphorylation at Thr421/Ser424 of phospho-S6 kinase, a downstream effector of mTOR, has been also shown to be strongly up-regulated during mitosis in tissues of rats and mice (42) . Using tissue sections of human carcinomas and cultured cancer cells we recently revealed that the active form of the · catalytic subunit of AMPK (PP-AMPK· Thr172 ), a pivotal upstream regulator of mTOR activity, is specifically increased in mitotic cells, with immunopositive PP-AMPK· Thr172 condensations displaying a dynamic distribution through all stages of mitosis in vivo (43, 44) . Our group has also revealed that PP-mTOR Ser2481 , but not total mTOR, appears to accumulate within nuclear dots displaying dynamic expression during the M-phase. The number of immunopositive condensations of PP-mTOR Ser2481 directly related with the percentage of mitotic cells, which suggested that this autophosphorylated form of mTOR may directly control cancer cell proliferation through its previously unrecognized capacity to interact with the mitotic apparatus (31) . We now present evidence that Serine 2481-autophosphorylation of mTOR couples with chromosome condensation and segregation during mitosis, which allows rapid and accurate identification of mitotic figures not only in cultured cancer cells but also in breast cancer biopsies. Our current findings strongly suggest that PP-mTOR Ser2481 -based immunohistochemical staining could be used as a novel high-contrast mitosis marker: a) PP-mTOR Ser2481 showed an enriched expression that correlated strongly and specifically with the mitotic status of cultured cancer cells, b) on the basis of double-immunofluorescence staining and confocal microscopy analyses, all mitotic figures positively marked with the Ser10-/Ser28-phosphorylated G 2 /M marker Histone H3 also co-expressed high levels of PP-mTOR Ser2481 , c) whereas PP-Histone H3 Ser10/Ser28 efficiently detected cells at the onset of mitosis (prophase, metaphase, weaker at the beginning of anaphase, but not during late anaphase, telophase and cytokinesis), PP-mTOR Ser2481 expression was seen in all stages of mitosis, with the phosphoprotein showing either an adjacent pattern to condensed chromatin (in early stages of mitosis) or a tight localization to the region of the mitotic spindle and midbody within the intracellular bridge (in late stages of mitosis and cytokinesis), d) PP-mTOR Ser2481 -based immunolabelling of paraffin-embedded tissue sections allowed for high-quality, reproducible detection of mitotic figures in human cancer tissues, e) there was a very good correlation between the mitotic figure counts performed on traditional H&E-stained tissue sections and those performed on anti-PP-mTOR Ser2481 -immunostained tissue sections of breast cancer biopsies, f) PPmTOR Ser2481 labelling significantly improves the mitotic count assessed by standard H&E sections in breast cancer core biopsies and, as a consequence, the histoprognostic grade of breast carcinomas could be upgraded in a significant proportion of cases.
Although we detected approximately three times as many M-phase cells with PP-mTOR Ser2481 immunolabelling than with H&E, we should acknowledge that this significantly higher sensitivity of PP-mTOR Ser2481 -based immunohistochemistry for mitotic figures solely occurs in breast cancer core biopsies but not in excisional ones. PP-mTOR Ser2481 staining was interpretable in few breast cancer lumpectomies and mastectomies and most excisional cases were excluded from evaluation. Since phosphorylation of proteins is rapidly reversible, it is likely that fixation needs to be carried out quickly after tissue sampling. Thus, inappropriate fixation of the tumor tissue within large specimens is most probably the cause for our poor results with PP-mTOR Ser2481 staining in excisional biopsies. Accordingly, immunohistochemical detection of mitotic figures using PP-Histone H3 Ser10 and PP-Histone Ser28 has previously been shown to be sensitive to delayed or elongated fixation (33, 45) . Moreover, it is obvious that the improvement of reproducibility of mitosis counts by applying PP-mTOR Ser2481 -based immunohistochemistry could not be determined in this preliminary study with overall low numbers of each tumor subtype. Also, the exact influence of PP-mTOR Ser2481 staining for the determination of changes in prognosis prediction in breast cancer subtypes due higher sensitivity of this novel mitotic marker remains to be established on a larger number of breast cancer samples.
As accurately indicated by Skaland et al (25) , mitotic counts strictly following the proper WHO count procedure (46) are not well liked by many pathologists and implementation of a worldwide general quality control system is not realistic. Moreover, suboptimal tissue fixation has been also demonstrated to impact adversely on ability to assess mitotic frequency resulting in a systematic downgrading of a proportion of breast cancer cases. This results in a significant reduction in the proportion of breast cancer cases assigned to grade 3 with resultant increase in grade 2 cases. In this regard, a breakthrough has been the demonstrated correlation between phosphorylation of nuclear histone H3, mitotic counts, and also prognosis in a homogeneous group of nodenegative invasive breast cancers under 55 years and long follow-up (24) . Using PP-Histone H3 Ser10 counting by digital analysis, the same group recently validated the prognostic value of proliferation measured by PP-Histone H3 Ser10 in a large series of invasive lymph node-negative breast cancer patients less than 71 years old (25) . Our current findings revealing for the first time that PP-mTOR Ser2481 immunolabelling may represent a simple and reliable method for quantifying proliferative potential as a mitosis marker in breast cancer core biopsies, further support the notion that 'application of an accurate high-contrast immunohistochemical mitosis marker would have the potential to make mitosis counting much faster, easier to assess, potentially wellreproducible, more accurate, and suitable for highly accurate counting by automated digital image analysis' (25) . A study is currently underway in our laboratory to confirm both the accuracy and the prognostic value of PP-mTOR Ser2481 as a novel high-contrast immunohistochemical mitosis marker in larger populations of human breast carcinomas.
